Glaukos Corporation (GKOS)
Glaukos Corporation operates in the Medical - Devices industry of the Healthcare sector, headquartered in Aliso Viejo, CA, US. The stock last traded at $171.68, up 0.34% on the session, giving a market capitalisation of $10.13B. On trailing twelve-month figures it carries a trailing P/E of -52.82, a net margin of -30.7%. Its beta of 0.77 implies it has historically moved less than the broad market.
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Glaukos Corporation is most often compared with the following Healthcare names: